Cargando…
Intratumoral Injection of an Adriamycin Immunoconjugate against Human Pancreatic Cancer Xenografts
We have evaluated the effect of an adriamycin conjugate of monoclonal antibody Nd2 (ADM‐Nd2) on the growth rate of SW1990 xenografts grown subcutaneously in athymic nude mice. Intravenous or intraperitoneal administration of radiolabeled Nd2 resulted in a maximum tumor accumulation of approximately...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920632/ https://www.ncbi.nlm.nih.gov/pubmed/8567399 http://dx.doi.org/10.1111/j.1349-7006.1995.tb03023.x |
_version_ | 1783317866260463616 |
---|---|
author | Kondo, Yasuyuki Chung, Yong‐Suk Sawada, Tetsuji Inui, Akimasa Yamashita, Yoshito Hirayama, Koji Nakata, Bunzo Ho, Jenny J. L. Kim, Young S. Sowa, Michio |
author_facet | Kondo, Yasuyuki Chung, Yong‐Suk Sawada, Tetsuji Inui, Akimasa Yamashita, Yoshito Hirayama, Koji Nakata, Bunzo Ho, Jenny J. L. Kim, Young S. Sowa, Michio |
author_sort | Kondo, Yasuyuki |
collection | PubMed |
description | We have evaluated the effect of an adriamycin conjugate of monoclonal antibody Nd2 (ADM‐Nd2) on the growth rate of SW1990 xenografts grown subcutaneously in athymic nude mice. Intravenous or intraperitoneal administration of radiolabeled Nd2 resulted in a maximum tumor accumulation of approximately 45% of the initial dose/g of tumor 3‐7 days after administration. However, administration into the tumor produced retention of 1200%ID/g 1 day after, with 50% of this high value remaining even at 7 days after administration. In contrast, intratumoral administration of a nonspecific immunoglobulin showed a lower initial retention and rapid loss of label. Both intravenously and intratumorally administered ADM‐Nd2 reduced the growth rate of SW1990 xenografts. While a single intravenous administration arrested growth for about two weeks, a single intratumoral injection prevented any increase in tumor size even 45 days after administration. Xenografts treated with ADM‐Nd2 showed degenerative changes at the histological level. Neither Nd2 alone nor Adriamycin alone inhibited growth when administered at the same dose as the conjugate. |
format | Online Article Text |
id | pubmed-5920632 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1995 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-59206322018-05-11 Intratumoral Injection of an Adriamycin Immunoconjugate against Human Pancreatic Cancer Xenografts Kondo, Yasuyuki Chung, Yong‐Suk Sawada, Tetsuji Inui, Akimasa Yamashita, Yoshito Hirayama, Koji Nakata, Bunzo Ho, Jenny J. L. Kim, Young S. Sowa, Michio Jpn J Cancer Res Article We have evaluated the effect of an adriamycin conjugate of monoclonal antibody Nd2 (ADM‐Nd2) on the growth rate of SW1990 xenografts grown subcutaneously in athymic nude mice. Intravenous or intraperitoneal administration of radiolabeled Nd2 resulted in a maximum tumor accumulation of approximately 45% of the initial dose/g of tumor 3‐7 days after administration. However, administration into the tumor produced retention of 1200%ID/g 1 day after, with 50% of this high value remaining even at 7 days after administration. In contrast, intratumoral administration of a nonspecific immunoglobulin showed a lower initial retention and rapid loss of label. Both intravenously and intratumorally administered ADM‐Nd2 reduced the growth rate of SW1990 xenografts. While a single intravenous administration arrested growth for about two weeks, a single intratumoral injection prevented any increase in tumor size even 45 days after administration. Xenografts treated with ADM‐Nd2 showed degenerative changes at the histological level. Neither Nd2 alone nor Adriamycin alone inhibited growth when administered at the same dose as the conjugate. Blackwell Publishing Ltd 1995-11 /pmc/articles/PMC5920632/ /pubmed/8567399 http://dx.doi.org/10.1111/j.1349-7006.1995.tb03023.x Text en |
spellingShingle | Article Kondo, Yasuyuki Chung, Yong‐Suk Sawada, Tetsuji Inui, Akimasa Yamashita, Yoshito Hirayama, Koji Nakata, Bunzo Ho, Jenny J. L. Kim, Young S. Sowa, Michio Intratumoral Injection of an Adriamycin Immunoconjugate against Human Pancreatic Cancer Xenografts |
title | Intratumoral Injection of an Adriamycin Immunoconjugate against Human Pancreatic Cancer Xenografts |
title_full | Intratumoral Injection of an Adriamycin Immunoconjugate against Human Pancreatic Cancer Xenografts |
title_fullStr | Intratumoral Injection of an Adriamycin Immunoconjugate against Human Pancreatic Cancer Xenografts |
title_full_unstemmed | Intratumoral Injection of an Adriamycin Immunoconjugate against Human Pancreatic Cancer Xenografts |
title_short | Intratumoral Injection of an Adriamycin Immunoconjugate against Human Pancreatic Cancer Xenografts |
title_sort | intratumoral injection of an adriamycin immunoconjugate against human pancreatic cancer xenografts |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920632/ https://www.ncbi.nlm.nih.gov/pubmed/8567399 http://dx.doi.org/10.1111/j.1349-7006.1995.tb03023.x |
work_keys_str_mv | AT kondoyasuyuki intratumoralinjectionofanadriamycinimmunoconjugateagainsthumanpancreaticcancerxenografts AT chungyongsuk intratumoralinjectionofanadriamycinimmunoconjugateagainsthumanpancreaticcancerxenografts AT sawadatetsuji intratumoralinjectionofanadriamycinimmunoconjugateagainsthumanpancreaticcancerxenografts AT inuiakimasa intratumoralinjectionofanadriamycinimmunoconjugateagainsthumanpancreaticcancerxenografts AT yamashitayoshito intratumoralinjectionofanadriamycinimmunoconjugateagainsthumanpancreaticcancerxenografts AT hirayamakoji intratumoralinjectionofanadriamycinimmunoconjugateagainsthumanpancreaticcancerxenografts AT nakatabunzo intratumoralinjectionofanadriamycinimmunoconjugateagainsthumanpancreaticcancerxenografts AT hojennyjl intratumoralinjectionofanadriamycinimmunoconjugateagainsthumanpancreaticcancerxenografts AT kimyoungs intratumoralinjectionofanadriamycinimmunoconjugateagainsthumanpancreaticcancerxenografts AT sowamichio intratumoralinjectionofanadriamycinimmunoconjugateagainsthumanpancreaticcancerxenografts |